Cal Baier-Anderson, Ph.D., is a Health Scientist.
A recent article posted on scienceline includes a claim that bacteria cannot develop resistance to silver, which is widely used as an antimicrobial. That assertion is not only false, but also dangerous. Read More
Richard Denison, Ph.D., is a Senior Scientist.
[Links to posts in this series: Part 1, Part 2, Part 3, Part 4, Part 5]
In this and my next two posts, I want to explore the question of whether EPA has sufficient authority under the Toxic Substances Control Act (TSCA) to effectively oversee nanotechnology. EPA (as well as the White House) maintains that the agency has ample statutory authority to do what’s needed to identify and address any potential risks nanomaterials may pose to consumers, the general public and the environment. I beg to differ. Read More
John Balbus, M.D., M.P.H., is Chief Health Scientist.
We and many others have made analogies between nanoparticles and asbestos. The purpose of the analogy has generally been to emphasize the long latency that can occur between exposure to toxic materials and the development and subsequent recognition of disease arising from that exposure. And, of course, the enormous legal and financial burden of failing to adequately consider risks before allowing widespread exposure. But a new study suggests that the analogy may be even stronger than we thought: It may extend to the capacity to cause mesothelioma, the rare form of cancer associated with exposure to asbestos. Read More
Cal Baier-Anderson, Ph.D., is a Health Scientist.
After posting to this blog the other day, I came across a brand new study characterizing the heterogeneity of carbon nanotubes. The authors of this study looked at 11 single-wall carbon nanotubes (SWCNTs) from 10 different suppliers and found that SWCNT composition varies dramatically depending on synthesis method, feedstock, purification steps, and other factors. Read More
Richard Denison, Ph.D., is a Senior Scientist.
Or at least the small screen. Coming to your local PBS station this month is a three-part series on nanotechnology called The Power of Small. The segments cover three facets of the much-needed social debate about nanotechnology: privacy issues (e.g., nano-enabled tracking devices), ethical issues (focusing on the potential to greatly extend human life expectancy), and, of course, the environmental risks and applications. Read More
Cal Baier-Anderson, Ph.D., is a Health Scientist.
With conventional chemicals, experience has allowed us to articulate general criteria based on chemical properties that identify chemicals of greatest concern. For example, persistent and bioaccumulative chemicals are assigned a high priority, whereas chemicals that quickly degrade and don’t build up in blood or tissue are, as a rule, likely to be of lower priority.
Concerns about nanomaterials arise from observations that properties that emerge or are greatly enhanced at the nanoscale can alter behavior, including biological activity. These properties make such materials different from conventional forms of the same chemicals. But can a general principle that nanomaterials pose a greater concern than their conventional counterparts be supported? Read More